G. David Roodman MD PhD

Kenneth Wiseman Professor of Medicine, Director of Hematology Oncology, Co-leader of the Hematopoiesis, Hematologic Malignancy and Immunology Program for the IU Simon Cancer Center, IU School of Medicine

Dr. Roodman was recruited to IUSM in 2011 to direct the Hematology Oncology Division in the Dept. of Medicine. Dr. Roodman previously was Vice Chair of Medicine for Research at University of Pittsburgh and the University of Texas Health Science Center at San Antonio. Dr. Roodman’s research interests focus on how cell-cell interactions among hematopoietic cells and cells in the bone marrow microenvironment control normal and malignant hematopoiesis and diseases affecting bone remodeling. Currently, his laboratory is involved in studies of the pathogenesis and progression of Paget's Disease and myeloma bone disease, and how cell-cell interactions between osteoclast and osteoblast precursors, and other cells in the marrow microenvironment lead to increased bone remodeling in Paget’s Disease, and the enhanced osteoclastogenesis and suppressed bone formation that contribute to myeloma cell growth and chemoresistance. Dr. Roodman has authored more than 350 peer reviewed publication and book chapters and is a member of the ASCI, AAP and a Fellow of the AAAS. He is currently president of the Cancer and Bone Society. His laboratory has been continuously funded by the NIH and VA Merit Review Program since 1981.

Mervin Yoder MD

Distinguished Professor, Director Wells Center for Pediatric Research, IU School of Medicine

Dr. Yoder has served as the Vice Chair for Basic Research in the Department of Pediatrics and the Director of the Herman B Wells Center for Pediatric Research since 2008. Dr. Yoder’s research interests include identifying the origin and mechanisms of mobilization of circulating endothelial colony forming cells (ECFCs), identifying a method to directly program ECFCs from pluripotent stem cell-derived mesoderm precursors, and defining the role of human endothelial colony forming cells in promoting neoangiogenesis in a variety of ischemic injuries in newborn or adult rodent models of human clinical disorders. He is a past president of the International Society for Experimental Hematology. He currently serves as Chair of the Committee for Stem Cells and Regenerative Medicine for the American Society of Hematology, is an Associate Editor for Stem Cells and Development, and is on the editorial board of 7 other journals related to hematology or cardiovascular medicine. He has published over 300 peer-reviewed manuscripts, editorials, book chapters, and books. He has received continuous NIH funding since 1997. He serves as an Associate Dean for Entrepreneurial Research where he has initiated new programs to facilitate faculty startup company development.